SCHEMBL2173660

SCHEMBL2173660

CCc1ccc[c]c1CN1CCNCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
SIGMAR1 Q99720 2/20 0.44
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A4 P31645 2/20 0.40
SLC6A2 P23975 1/20 0.40
CHRM2 P08172 2/20 0.38
CYP1A2 P05177 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
APOBEC3A P31941 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
CXCR4 P61073 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855361 0.81 LMNA (0.55) LMNASIGMAR1CHRM2CXCR4KMT2A
SCHEMBL14939663 0.77 LMNA (0.67) LMNASIGMAR1HTR1ADRD2DRD4
SCHEMBL4307026 0.77 LMNA (0.47) LMNASIGMAR1SLC6A4CHRM2CYP1A2
SCHEMBL18398017 0.75 HTR2C (0.51) LMNASIGMAR1HTR1ADRD2DRD4
SCHEMBL28919135 0.75 LMNA (0.51) LMNASIGMAR1SLC6A4CHRM2CYP1A2
SCHEMBL7393057 0.75 SIGMAR1 (0.50) LMNASIGMAR1HTR1ADRD2HTR2A
SCHEMBL7392732 0.72 SIGMAR1 (0.41) LMNASIGMAR1CXCR4
SCHEMBL64051 0.72 GABRA1 (0.41) SIGMAR1
SCHEMBL15966079 0.72 LMNA (0.59) LMNASIGMAR1HTR1ADRD2DRD4
SCHEMBL18398021 0.71 SIGMAR1 (0.46) SIGMAR1HTR1ADRD2DRD4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP claimed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO claimed
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 LMNA 4836/4885SIGMAR1 165/4885HTR1A 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.